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Abstract
Background: The Multiple Sclerosis International Quality Of Life (MusiQoL) questionnaire, a 31-item,
multidimensional, self-administrated questionnaire that is available in 14 languages including Spanish, has been
validated using a large international sample. We investigated the validity and reliability of the Spanish version of
MusiQoL in Spain.
Methods: Consecutive patients with different types and severities of multiple sclerosis (MS) were recruited from 22
centres across Spain. All patients completed the MusiQoL questionnaire, the 36-Item Short Form (SF-36) health
survey, and a symptoms checklist at baseline and 21 days later. External validity, internal consistency, reliability and
reproducibility were tested.
Results: A total of 224 Spanish patients were evaluated. Dimensions of MusiQoL generally demonstrated a high
internal consistency (Cronbach’s alpha: 0.70-0.92 for all but two MusiQoL domain scores). External validity testing
revealed that the MusiQoL index score correlated significantly with all SF-36 dimension scores (Pearson’s
correlation: 0.46-0.76), reproducibility was satisfactory (intraclass correlation coefficient: 0.60-0.91), acceptability was
high, and the time taken to complete the 31-item questionnaire was reasonable (mean [standard deviation]: 9.8
[11.8] minutes).
Conclusions: The Spanish version of the MusiQoL questionnaire appears to be a valid and reliable instrument for
measuring quality of life in patients with MS in Spain and constitutes a useful instrument to measure health-related
quality of life in the clinical setting.
Background
Health-related quality-of-life (HRQoL) measurements
have become an important instrument in population
health assessment, treatment evaluation and care man-
agement [1-3]. HRQoL indicators depend on the com-
pletion of a well-validated questionnaire that assesses
health status in individual patients as perceived by
themselves through the physical, mental, social and
behavioural components of well-being and function [4].
Thus, one major challenge in elaborating the content of
the HRQoL dimensions to be measured is to ensure
that patients’ perceptions are accurately taken into
account [5]. Specific HRQoL questionnaires that are
available for MS in Spain are FAMS (Functional Assess-
ment of Multiple Sclerosis) [6] and MSQOL-54 (Multi-
ple Sclerosis Quality of Life 54) [7]. However, both of
these are based on generic QoL instruments.
The Multiple Sclerosis International Quality of Life
(MusiQoL) questionnaire, a specific, self-administered,
multidimensional questionnaire, was co-developed and
initially validated in 15 countries including Spain [8]. The
initial item pool of the Functional Assessment of Multi-
ple Sclerosis included items from the general version of
the Functional Assessment of Cancer Therapy quality of
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life instrument. The other items were generated by
patients, providers, and literature review. The MSQOL-
54 has been adapted from the SF36 measure by the addi-
tion of five unchanged SF36 scales, three “altered” SF36
scales (one item added to each scale), and five new scales
incorporated 15 additional items. Modifying existing
measures by adding MS-specific items was not found to
be as useful. The content of the QoL questionnaires is
now well-recognized as more appropriate when it is
derived from the patients’ point of view/patients’ inter-
views. MusiQoL questionnaire specifically reflects the
point of view of patients with MS on the impact of the
disease on their daily life and is anchored in an explicit
conceptual approach as recommended by McKenna [5].
We investigated the validity and reliability of the Spanish
version of MusiQoL in Spain.
Methods
Patients
The patients enrolled in the validation study consisted of
inpatients and outpatients who were followed in an inter-
national multicentre study coordinated by an interna-
tional steering committee (15 senior neurologists, two
experts in HRQoL, one expert in health economics and
two external advisors). The inclusion criteria were a diag-
nosis of MS according to Poser [9] or McDonald [10] cri-
teria as the main diagnosis for more than 6 months, age
older than 18 years, informed consent to participate in
the study and Spanish as the native language. The main
exclusion criteria included a main diagnosis other than
MS, dementia, current severe relapses, inability to com-
plete the questionnaire independently and withdrawal of
consent. Patients were enrolled between January 2004
and February 2005 from 22 centres distributed through-
out Spain.
Study design
Patients were evaluated at inclusion and re-tested a mean
(standard deviation) of 21 (7) days later. The self-admi-
nistered survey materials that were completed by the
patients included the MusiQoL questionnaire, one check-
list of 14 symptoms reported by patients suffering from
MS (e.g. lack of sensation in touch, lack of sensation in
position, fatigue, visual problems, urinary incontinence)
and the 36-Item Short Form (SF-36) health survey [11].
The SF-36 is the most widely used generic QoL scale
in MS, consisting of 36 items that describe eight dimen-
sions: Physical Functioning (PF), Social Functioning
(SF), Role-Physical Problems (RPP), Role-Emotional Pro-
blems (REP), Mental Health (MH), Vitality (VIT), Bodily
Pain (BP), and General Health (GH). Each dimension is
scored from 0-100; the higher the score, the better the
perceived state of health.
MusiQoL comprises 31 items that describe nine
dimensions (Additional file 1 and Additional file 2). Each
dimension is named according to its constitutive items,
as follows: activities of daily living (ADL, 8 items), psy-
chological well-being (PWB, 4 items), symptoms (SPT, 3
items), relationships with friends (RFr, 4 items), relation-
ships with family (RFa, 3 items), relationship with the
healthcare system (RHCS, 3 items), sentimental and sex-
ual life (SSL, 2 items), coping (COP, 2 items) and rejec-
tion (REJ, 2 items). Each item was answered using a six-
point Likert scale, where 1 = ‘never/not at all’, 2 = ‘rarely/
a little’, 3 = ‘sometimes/somewhat’, 4 = ‘often/a lot’, 5 =
‘always/very much’, 6 = ‘not applicable’. The negatively
worded item scores were reversed so that higher scores
indicated a higher level of HRQoL. For each patient, the
score of each dimension was obtained by computing the
mean of the item scores of the dimension. If fewer than
half of the items were missing, the mean of the non-miss-
ing items was substituted for the missing items. All
dimension scores were linearly transformed to a 0-100
scale. A global index score was computed as the mean of
the dimension scores.
In addition, an experienced local neurologist collected
sociodemographic data, clinical history (related or unre-
lated to MS), and information on the type of treatment
for MS. The neurologist also rated the following: Poser
classification (or McDonald classification), the Expanded
Disability Status Scale (EDSS) [12], the Ambulation
Index (AI) for MS [13], the Folstein Mini-Mental State
Examination (MMSE) [14] and the Clinical Global
Impression (CGI) of severity scale (mild, moderate,
severe) [15]. A detailed physical examination was con-
ducted at baseline and any abnormalities in the organ
systems inspected were noted.
At re-testing, patients completed the same question-
naire and one additional question assessing changes in
health status. Neurologists collected data on current
care and treatment of MS, rated the scores for the EDSS
and CGI, and assessed patient health status compared
with that reported at the initial inclusion stage (i.e. wor-
sened, remaining stable, improved).
Statistical analyses
The linguistic transcultural equivalence was ensured by
the codevelopment process, including interview and
selection of items conducted in Spain.
The multidimensional structure (construct validity) of
the Spanish version of the MusiQoL questionnaire was
checked using multitrait/multi-item analysis program
(MAP) [16] analyses. Internal structural validity was
assessed using item-dimension correlations: item internal
consistency (IIC) was assessed by correlating each item
with its scale (correlation of 0.4 for supporting item
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internal consistency [IIC]) and item discriminant validity
(IDV) was assessed by determining the extent to which
items correlates with the dimension they are hypothe-
sized to represent than with the other ones. Floor and
ceiling effects were assessed by the homogeneous reparti-
tion of the response distribution. For each dimension,
internal consistency reliability was assessed by Cron-
bach’s alpha coefficient. A Cronbach’s alpha coefficient of
at least 0.7 was expected for each scale [17]. The unidi-
mensionality of each scale was assessed using Rasch ana-
lyses: item goodness-of-fit statistics (INFIT) and
coefficient of Loevinger (H). INFIT ranging between 0.7
and 1.2 and H of at least 0.40 ensure that all the items of
the scale tend to measure the same concept.
To explore external validity, relations between: i) dimen-
sions of MusiQoL and the SF-36, and ii) dimensions of
MusiQoL and the 14-symptom scale assessing miscella-
neous domains, were examined using Pearson’s correlation
coefficients (r). The underlying assumption was that Musi-
QoL dimension scores would be more correlated with the
scores of similar dimensions from the other instruments
than with the scores of dissimilar dimensions [8]. The dis-
criminant validity was determined by assessing the asso-
ciations between the MusiQoL dimension scores and
sociodemographic and clinical features. For qualitative
variables, mean dimension scores of the MusiQoL were
compared across patient groups that were expected to dif-
fer (e.g. MS forms, CGI, gender, family status, educational
level, employment status, housing) using one-way analysis
of variance. Quantitative variables (e.g. MMSE, AI, EDSS
score, age) were analysed using Pearson’s correlation
coefficients.
Reproducibility was tested through test-re-test reliability
using intraclass correlation coefficients (ICC) between the
two successive assessments in patients with stable clinical
disease. Stable clinical disease was defined using both the
physician clinical global impression and the EDSS.
Acceptability was assessed by calculating the average
time of completion of the MusiQoL questionnaire and
the percentage of missing data per dimension.
Data analyses were performed using SPSS 11.0, MAP-
R, and WINSTEP software.
Results
Patient characteristics
The study sample included 224 Spanish patients with MS
(Table 1). The mean (standard deviation [SD]) age was 39
(10) years (min = 20/max = 63). More than 75% of
patients had clinically definite MS according to Poser cri-
teria. Almost 80% were patients with the relapsing-remit-
ting form of MS, and there were no patients with clinically
isolated syndrome. Mean EDSS was 2.9 (SD: 2.0; range 0-
8) with a mean disease duration of 11 years (range: 1-36).
Construct Validity and Internal Structural Validity
The correlation of each item was higher with the Musi-
QoL dimension of which it was part than with any
other dimension, except for the items of the coping
dimension. Floor and ceiling effects can be considered
as satisfactory (ceiling effects of RFa and RHCS dimen-
sions were high, 33.0 and 41.1 respectively; Table 2).
Dimensions of the MusiQoL showed satisfactory inter-
nal consistency (Cronbach’s alpha: 0.70-0.92), except for
the dimensions of RFa (Cronbach’s alpha: 0.67) and
RHCS (Cronbach’s alpha: 0.53; Table 2).
The overall scalability was satisfactory except for 2
dimensions: the SPT dimension showed an INFIT statistic
and a Loevinger coefficient H outside the acceptable
ranges, the RHCS dimension provided a coefficient H
inferior to 0.40.
External validity
The concepts covered by the MusiQoL and the SF-36
are not largely overlapping. MusiQoL dimension scores
Table 1 Baseline characteristics of the study population (n = 224)
Variable n (%)
Age, mean (SD), years (n = 224) 39 (10)
Sex (n = 223) Female 157 (70.4)
Male 66 (29.6)
Poser classification (n = 223) Clinically defined MS 172 (77.1)
Laboratory defined MS 49 (22.0)
Clinically probable MS 2 (0.1)
Clinical form of MS (n = 222) Relapsing-remitting 176 (79.3)
Secondary progressive 40 (18.0)
Primary progressive 6 (2.7)
Disease duration, mean (SD), range, years 10.6 (7.2)
1-36
EDSS score, mean (SD), range 2.9 (1.9)
0-8
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; SD, standard deviation.
Fernández et al. BMC Neurology 2011, 11:127
http://www.biomedcentral.com/1471-2377/11/127
Page 3 of 10
Table 2 MusiQoL dimension scale characteristics
Dimension (number of items) Mean (SD) MV
(%)
Cronbach’s
alpha
IIC,
range
IDV,
range
Floor effect, % Ceiling effect, % H INFIT
Activities of Daily Living (8) 57.04 (25.96) 1.8 0.92 0.67-0.80 -0.02 to 0.51 0.9 4.5 0.65 0.87-1.19
Psychological Well-Being (4) 52.95 (23.80) 0.4 0.88 0.70-0.79 -0.01 to 0.60 2.2 4.0 0.68 0.80-1.12
Relationships with Friends (3) 68.61 (22.51) 6.3 0.80 0.59-0.73 -0.02 to 0.33 1.3 13.4 0.61 0.91-1.12
Symptoms (4) 66.45 (22.64) 0.9 0.70 0.43-0.59 -0.02 to 0.51 0.0 11.2 0.37 0.79-1.20
Relationships with Family (3) 82.92 (17.82) 1.3 0.67 0.47-0.56 0.01-0.43 0.0 33.0 0.44 0.98-1.02
Relationship with Healthcare System (3) 86.79 (16.02) 0.4 0.53 0.25-0.40 -0.02 to 0.23 0.0 41.1 0.30 0.82-1.15
Sentimental and Sexual Life (2) 73.14 (26.52) 16.1 0.76 0.65 0.04-0.38 3.1 25.0 0.68 0.91-1.10
Coping (2) 59.31 (28.02) 5.4 0.75 0.60 0.13-0.65 3.1 15.2 0.65 0.96-1.01
Rejection (2) 83.11 (21.62) 7.1 0.75 0.66 0.10-0.43 0.0 1.3 0.56 0.94-1.04
Index 70.32 (13.71)
H Loevinger coefficient; IDV, item discriminant validity; IIC, item internal consistency; INFIT item goodness-of-fit (Rasch statistics); MV, percentage of missing values; SD, standard deviation.
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were only moderately correlated with scores of the SF-
36, except for expected correlation of ADL with physical
functioning and vitality; and PWB and COP with MH
(p < 0.05; Table 3). The situation was similar when
comparing the MusiQoL dimensions with the self-
reported 14-symptom scale. ADL on MusiQoL was, at
the most, moderately correlated with all components of
the 14-symptom scale (p < 0.05), except for ‘inability to
swallow’ (Table 3).
Discriminant validity
The discriminant validity of MusiQoL was assessed by
clinical and sociodemographic characteristics (Tables 4
and 5). There were significant differences based on MS
classification in the dimensions of ADL, COP and REJ
and the index score (p < 0.05). Patients with secondary
progressive MS generally had lower scores (34.5-74.7)
than did patients with relapsing-remitting MS (RRMS)
(62.4-85.4) or primary progressive MS (31.0-81.3). Dif-
ferences were also observed when comparing dimension
scores by severity rated on the CGI; patients with mild
(56.1-88.1) or moderate (47.8-87.4) disease scored higher
than those with severe disease (32.6-80.0) for all the
domains including the index.
A significant difference was shown in SPT scores in
patients with cognitive problems (not including the
exclusion criterion of dementia). The time from first
symptoms did not correlate with any of the MusiQoL
domains. EDSS was only moderately correlated with
ADL dimension (p > 0.01) (Table 4). No significant dif-
ferences were found according to family history of MS.
Patients actually treated and patients treated for the
symptoms of relapse did not show significant differences
in HRQoL (data not shown).
Women were found to have recorded lower scores than
men for PWB. Differences were observed when compar-
ing ADL and SSL scores by family status, with patients
living with relatives/family scoring higher for ADL, and
couples scoring the highest for SSL and those living with
relatives/family (p < 0.05). Patients with a tertiary educa-
tion had higher scores in the dimensions of ADL, PWB,
SPT and RHCS and the index score than did those with a
primary or secondary education. Higher scores were also
found among students and workers than those who were
unemployed in the domains of ADL, PWB, SPT, COP
Table 3 Pearson’s correlations between MusiQoL and SF-36, and the 14 self-reported symptom scales
MusiQoL dimensions
SF-36 dimensions ADL PWB RFr SPT RFa RHCS SSL COP REJ Index
Physical functioning 0.729** 0.203** 0.087 0.311** 0.178** 0.217** 0.195** 0.282** 0.248** 0.496**
Social functioning 0.515** 0.347** 0.212** 0.441** 0.178** 0.198** 0.275** 0.373** 0.222** 0.541**
Role - physical 0.603** 0.409** 0.078 0.514** 0.181** 0.177** 0.118 0.315** 0.300** 0.551**
Role - emotional 0.443** 0.443** 0.099 0.527** 0.115 0.126 0.164* 0.489** 0.274** 0.559**
Mental health 0.383** 0.665** 0.241** 0.504** 0.310** 0.145* 0.389** 0.654** 0.465** 0.760**
Vitality 0.688** 0.577** 0.157* 0.550** 0.258** 0.214** 0.354** 0.532** 0.364** 0.699**
Bodily pain 0.431** 0.392** 0.064 0.471** 0.149* 0.180** 0.157* 0.283** 0.219** 0.463**
General health 0.542** 0.347** 0.128 0.360** 0.116 0.200** 0.265** 0.450** 0.247** 0.521**
14-symptom scales ADL PWB RFr SPT RFa RHCS SSL COP REJ Index
Lack of sensation in touch -0.295** -0.057 0.070 -0.112 0.068 0.126 -0.160 0.062 -0.019 -0.100
Lack of sensation in position -0.332** -0.087 0.109 -0.192* 0.030 0.063 -0.134 -0.066 -0.030 -0.173
Involuntary body movements -0.433** -0.083 0.040 -0.133 -0.073 -0.018 0.001 -0.213* -0.105 -0.249*
Vibration in legs or arms -0.462** -0.185* -0.060 -0.274** -0.083 -0.092 -0.083 -0.204* -0.167 -0.348**
Weakness in limbs -0.575** -0.106 -0.047 -0.214** -0.031 -0.048 0.000 -0.147 -0.149 -0.242**
Tingling in limbs -0.329** -0.132 0.025 -0.246** -0.040 -0.071 -0.010 -0.067 -0.127 -0.272**
Inability to swallow -0.054 -0.155 -0.011 -0.056 -0.232 -0.080 -0.202 -0.279* -0.052 -0.269*
Involuntary eye movements -0.215* -0.064 0.020 -0.205 0.102 0.082 -0.046 -0.102 0.032 -0.151
Visual problems -0.311** -0.185* 0.051 -0.423** 0.062 -0.062 -0.138 -0.087 -0.124 -0.321**
Problems concentrating -0.425** -0.364** -0.114 -0.587** -0.050 -0.112 -0.134 -0.323** -0.236** -0.522**
Difficulty concentrating -0.326** -0.224* -0.235* -0.395** -0.048 -0.060 0.001 -0.234* -0.388** -0.422**
Fatigue -0.553** -0.222** -0.075 -0.336** -0.004 -0.034 -0.077 -0.303** -0.184* -0.373**
Urinary incontinence -0.404** -0.118 -0.074 -0.220* -0.078 -0.019 -0.212* -0.058 -0.050 -0.239*
Bowel incontinence -0.274* -0.190 -0.020 -0.291** -0.058 -0.113 -0.088 -0.046 -0.114 -0.182
Bold values indicate significant correlation.
*p < 0.05; **p < 0.01.
ADL, activities of daily living; COP, coping; PWB, psychological well-being; REJ, rejection; RFa, relationships with family; RFr, relationships with friends; RHCS,
relationship with healthcare system; SPT, symptoms; SSL, sentimental and sexual life.
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and REJ and the index score. For the ADL and SPT
domains, patients living with relatives had significantly
higher scores than those living alone (Table 5).
Reproducibility
The number of patients defined as stable between the 2
assessments was 172 according to the physician CGI
definition and 190 according to the EDSS. The reprodu-
cibility of the MusiQoL domains scores and index score
were satisfactory irrespective of the definition of stabi-
lity, with intraclass correlation coefficients ranging from
0.60-0.91 (Table 6).
Acceptability
Acceptability was high. Mean (SD) time for completion
of the MusiQoL items was 9.8 (11.8) minutes in the
patient group as a whole. Mean (SD) time for comple-
tion was 9.7 (12.7) minutes in patients with RRMS, 11.6
(7.7) minutes in patients with primary progressive MS
and 9.8 (7.4) minutes in patients with secondary pro-
gressive MS. The proportion of missing values per
dimension was considered to be acceptable, ranging
from 0.4 to 7.1% with the exception of the SSL dimen-
sion, which had 16.1% of values missing.
Discussion
The MusiQoL study has been a major effort to develop
a multidimensional specific HRQoL instrument for
patients with MS. It has been developed simultaneously
in 1992 patients from 15 countries and in 14 languages
[8], using an standardized methodology [18]. It takes
into account patients’ concerns about QoL, extracting
items such as sentimental and sexual life, which patients
have described as important for them, and that are not
included in other previous instruments [19,20].
Some HRQoL instruments have already been validated
in patients with MS in Spain [6,7]. The Spanish version of
FAMS was validated in a study that assessed 625 patients
with MS recruited in an outpatient clinic setting from 58
hospitals in Spain. Of these, 74% were patients with
RRMS, with a mean age of 37 years, a mean disease dura-
tion of 8.8 years and a mean EDSS of 3 points at baseline.
The scale showed very good subscale homogeneity com-
parable to that of the original English version. The Spanish
version was not tested for external validity with other
HRQoL scales [6].
A transcultural adaptation of the MSQOL-54 has also
been validated in a Spanish version. Ten interviews were
carried out with 5 men and 5 women with MS, aged 21-
Table 4 MusiQoL dimension scores, by clinical characteristics and medical history
MusiQoL dimension
Variable ADL PWB RFr SPT RFa RHCS SSL COP REJ Index
MS classification
Relapsing-remitting (n = 176) Mean 63.5 54.3 69.3 67.7 83.5 87.3 73.6 62.4 85.4 72.0
SD 24.0 23.4 22.5 22.2 17.5 16.5 25.8 26.2 20.0 13.0
Primary progressive (n = 6) Mean 31.0 50.0 76.4 65.6 81.9 80.6 72.5 57.5 81.3 65.0
SD 18.5 22.0 13.4 28.2 25.0 17.2 37.9 31.4 25.9 9.2
Secondary progressive (n = 40) Mean 34.5 49.1 64.9 62.9 80.1 85.0 70.5 46.9 74.7 63.3
SD 18.9 24.7 23.7 23.2 18.7 13.7 29.7 31.8 25.6 15.9
p-value < 0.001 0.435 0.402 0.475 0.569 0.464 0.854 0.009 0.021 0.011
Clinical global impression
Mild (n = 118) Mean 68.7 56.1 68.2 70.8 83.0 88.1 74.0 63.5 87.0 73.2
SD 23.9 24.0 23.8 22.1 17.8 14.3 26.0 26.4 19.8 13.2
Moderate (n = 70) Mean 47.8 50.2 70.3 61.1 85.4 87.4 75.0 61.2 80.0 69.0
SD 20.5 22.4 21.9 20.7 17.5 17.5 25.5 28.2 22.4 12.5
Severe (n = 24) Mean 32.6 49.3 69.4 62.8 73.6 80.0 63.3 40.9 74.4 59.9
SD 17.6 23.6 18.5 27.4 18.6 17.7 27.7 28.1 26.0 15.4
p-value < 0.001 0.166 0.843 0.012 0.023 0.074 0.284 0.002 0.015 0.003
MMSE (n = 221) r 0.29 0.15 0.05 0.23 0.04 0.12 0.09 0.15 0.25 0.26
p-value < 0.001 0.029 0.488 0.001 0.575 0.085 0.204 0.028 < 0.001 0.001
Ambulation Index (n = 220) r -0.62 -0.12 0.00 -0.19 -0.16 -0.17 -0.07 -0.26 -0.20 -0.34
p-value < 0.001 0.075 0.985 0.006 0.022 0.011 0.378 < 0.001 0.005 < 0.001
EDSS (n = 221) r -0.63 -0.14 0.02 -0.25 -0.04 -0.18 -0.06 -0.29 -0.26 -0.35
p-value < 0.001 0.045 0.789 < 0.001 0.511 0.008 0.399 0.001 < 0.001 < 0.001
Bold values: p < 0.05.
ADL, activities of daily living; ANOVA, analysis of variance; CIS, clinically isolated syndrome; COP, coping; EDSS, Expanded Disability Status Scale; MMSE, Mini
Mental Score Examination; PWB, psychological well-being; r, correlation coefficient; REJ, rejection; RFa, relationships with family; RFr, relationships with friends;
RHCS, relationship with healthcare system; SPT, symptoms; SSL, sentimental and sexual life.
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54 years, with different education levels and EDSS
scores ranging from 1.0 to 8.0. The translated version
shows that the Spanish pre-test version is comprehensi-
ble and its administration feasible in patients with MS.
The psychometric properties must be evaluated in the
next phase of the project [7].
The Patient-Reported Indices for Multiple Sclerosis
(PRIMUS) is a recently developed scale that comprises
three scales for assessing symptoms, activity limitations
and QoL in MS. It was translated using a dual-panel
process and validated in eight languages, including
Spanish. For the Spanish validation, 87 patients were
tested, with a mean age of 43 years and 9 years of dis-
ease duration at baseline. Forty-seven percent of these
patients had RRMS. No data about EDSS at the moment
of the study are provided. Most of the tests showed
Table 5 MusiQoL dimension scores, by sociodemographic characteristics
Variable ADL PWB RFr SPT RFa RHCS SSL COP REJ Index
Sex
Female (n = 157) Mean 58.4 51.0 69.8 66.0 82.7 86.8 74.6 58.8 83.8 70.5
SD 25.4 24.0 21.0 23.0 18.4 16.0 26.2 27.8 22.1 13.6
Male (n = 66) Mean 54.5 58.4 66.3 68.1 83.3 86.6 70.2 61.3 81.7 70.5
SD 26.8 21.9 25.6 21.5 16.8 16.2 27.3 27.9 20.8 13.8
p-value 0.316 0.033 0.311 0.541 0.821 0.915 0.292 0.552 0.538 0.998
Family status
Couple (n = 145) Mean 52.8 50.5 68.7 64.7 83.6 86.5 75.6 60.0 82.8 69.5
SD 26.1 22.7 21.2 22.7 18.1 16.3 23.9 28.0 22.1 13.8
Single (n = 33) Mean 60.9 58.1 70.7 71.7 77.0 90.4 60.7 60.2 85.6 70.6
SD 21.4 20.8 19.2 14.9 19.9 13.0 30.4 26.8 16.9 12.0
With relatives or family (n = 45) Mean 69.0 58.1 67.5 69.3 85.2 84.9 70.8 57.8 82.4 74.8
SD 24.4 27.3 28.3 26.1 14.6 17.1 32.9 28.4 23.8 13.6
p-value 0.001 0.072 0.837 0.190 0.104 0.309 0.0048 0.899 0.776 0.214
Education level
Primary (n = 69) Mean 49.8 47.4 68.5 62.0 83.0 88.3 75.2 57.1 82.3 67.8
SD 27.0 20.9 21.9 23.1 18.4 15.7 25.5 29.6 24.7 13.1
Secondary (n = 82) Mean 57.1 48.9 64.8 63.5 80.1 83.2 68.6 56.3 80.3 68.1
SD 23.9 24.6 22.5 20.6 20.2 19.1 27.2 26.2 23.4 14.0
Tertiary (n = 69) Mean 64.1 63.2 73.4 74.6 85.5 89.4 76.1 66.3 87.3 75.6
SD 25.2 21.6 22.5 22.6 14.0 11.2 27.1 26.5 14.7 12.2
p-value 0.005 < 0.001 0.074 0.001 0.181 0.040 0.223 0.062 0.155 0.004
Employment status
Student (n = 17) Mean 72.9 55.3 74.0 76.8 88.7 90.7 77.1 55.9 90.6 75.8
SD 21.5 19.3 20.8 21.7 12.1 11.7 24.3 28.0 9.7 10.2
Worker (n = 104) Mean 64.0 57.0 70.2 71.2 83.5 86.6 75.1 65.2 87.0 73.9
SD 25.4 22.2 23.4 21.2 17.1 15.3 24.4 27.7 19.4 12.5
Unemployed (n = 102) Mean 47.7 48.9 66.4 60.3 81.3 86.2 70.4 54.6 78.2 66.2
SD 23.6 25.1 21.8 22.4 19.3 17.3 29.2 27.0 24.1 14.0
p-value < 0.001 0.047 0.319 < 0.001 0.260 0.562 0.442 0.025 0.007 0.001
Housing
Own home (n = 168) Mean 53.3 51.9 69.6 64.8 82.5 86.2 74.8 59.8 83.3 69.6
SD 25.3 22.6 21.0 22.5 18.5 16.5 24.9 27.8 21.2 13.7
With relatives (n = 54) Mean 70.1 57.8 66.2 72.5 84.3 88.6 66.8 59.4 83.7 74.3
SD 23.3 25.8 26.7 21.9 15.8 14.8 32.3 28.0 22.6 12.6
p-value < 0.001 0.109 0.345 0.031 0.526 0.336 0.097 0.935 0.914 0.075
Age r -0.36 -0.16 0.09 -0.21 -0.05 -0.03 -0.07 -0.01 -0.03 -0.32
p-value < 0.001 0.019 0.220 0.002 0.453 0.621 0.333 0.902 0.674 0.006
Bold values: p < 0.05.
ADL, activities of daily living; ANOVA, analysis of variance; COP, coping; DS, p < 0.05; NS, not significant; PWB, psychological well-being; r, correlation coefficient;
REJ, rejection; RF, relationships with family; RFr, relationships with friends; RHCS, relationship with healthcare system; SPT, symptoms; SSL, sentimental and sexual
life
Fernández et al. BMC Neurology 2011, 11:127
http://www.biomedcentral.com/1471-2377/11/127
Page 7 of 10
good unidimensionality and internal consistency, repro-
ducibility and construct validity in each translated lan-
guage, including Spanish [21].
Our sample of Spanish patients with MS has similar
clinical characteristics (80% RRMS, disease duration of
10.6 years and mean EDSS of 2.9) to the previously
described MS samples [22], so they are perfectly
comparable.
This study confirms the process of validation (external
validity, internal consistency, reliability and reproducibil-
ity) of the Spanish version of the MusiQoL. Our results
for validation are satisfactory and similar to those of the
international patient sample [8]. This indicates a major
strength of the MusiQoL regarding the simultaneous
process of validation in different countries.
In the present study, the SF-36 was used for external
validation. The SF-36 is a generic questionnaire that has
previously been adequately validated in Spanish patients
with other health conditions [23-30] and has been used
occasionally in patients with MS [31-33]. MusiQoL
dimension scores were, in our study, at most moderately
correlated with the scores of SF-36, indicating that the
two scales do not overlap.
The largest study using the SF-36 for the evaluation of
QoL in Spanish patients with MS included 705 patients,
78% of whom had RRMS, with a mean age of 40.5 years
and a median EDSS score of 2.5. These characteristics
are similar to those of the patients included in our study
and the scores for the eight SF-36 dimensions are also
similar. The previous study reported lower physical QoL
in patients with higher EDSS scores, but there was no
apparent differences in the SF-36 dimensions when stra-
tified by EDSS [31].
We found significant correlations between ADL scores
and clinical indices such as EDSS and Ambulation Index,
as other authors found [34,35], and the clinical global
impression was significantly different in patients with
mild or moderate disease, who scored higher than those
with severe disease in every MusiQoL domain. These
results are similar to the results found in the Spanish
FAMS validation study where higher EDSS scores pre-
dicted worse scores on all aspect of QoL [8]. PWB score
was higher for the male compared to the females. This is
a usual result, reported by other authors [36]. These find-
ings emphasize the usefulness of HRQoL instruments,
specifically MusiQoL, and indicate the utility of the ADL
dimension in reporting the clinical status of patients with
MS from their own point of view [37].
The present study had several limitations. The popula-
tion differs to that in the original study by Simeoni et al
[8] as there were no patients with clinically isolated syn-
drome and only 6 patients with primary progressive MS,
preventing the validity of the questionnaire from being
evaluated in these groups. Further work could be con-
ducted prospectively in a sample with representative
proportions of patients in terms of clinical subtypes of
MS. The missing values for most MusiQoL dimensions
were considered to be acceptable (range: 0.4-7.1%),
except for the SSL dimension, which had 16.1% missing
values. This highlights that SSL may be an underre-
ported deficit in patients with MS. The external validity
was explored by studying relationships between dimen-
sions of MusiQoL and dimensions of SF36, because the
SF36 was the single questionnaire available in the
needed versions for the initial international validation
study; it could be completed by studying correlations of
Musiqol and other widespread Spanish MS-specific
instruments.
Although MusiQoL could be used with advantage in
other Spanish-speaking countries, given its demon-
strated acceptable cross-cultural validity [8], small adap-
tations and further validations would be necessary to
ensure reliable application within each of those settings.
Even with all these cautions, we point out its potential
use as an outcome measure in clinical settings, particu-
larly in multinational clinical trials.
Table 6 Reproducibility of MusiQoL scores in patients with stable physician CGI (n = 172) and EDSS scores (n = 190)
Physician CGI
(n = 172)*
EDSS
(n = 190)**
Activities of Daily Living 0.89 0.90
Psychological Well-Being 0.81 0.90
Relationships with Friends 0.73 0.73
Symptoms 0.83 0.84
Relationships with Family 0.60 0.76
Relationship with Healthcare System 0.69 0.69
Sentimental and Sexual Life 0.78 0.79
Coping 0.80 0.79
Rejection 0.86 0.84
Index 0.91 0.91
CGI, Clinical Global Impression; EDSS, Expanded Disability Status Scale.
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Conclusions
The Spanish version of the MusiQoL instrument has
been shown to be a valid and reliable instrument for
measuring HRQoL in patients with MS. Acceptability
was high and time for completion short, and thus Musi-
QoL constitutes a useful instrument to measure HRQoL
in the clinical setting in Spain.
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